Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.59 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.56 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.56 |
| ▸ | GLP1R | P43220 | 4/20 | 0.56 |
| ▸ | VIPR2 | P41587 | 3/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567445 | 0.97 | TFPI (0.61) | TFPIVIPR1GLP1RVIPR2 | |
| SCHEMBL30432094 | 0.94 | VIPR1 (0.61) | TFPIVIPR1GLP1RVIPR2 | |
| SCHEMBL30633108 | 0.94 | KISS1R (0.61) | TFPIKISS1RVIPR1GLP1RVIPR2 | |
| SCHEMBL29649210 | 0.92 | TFPI (0.56) | TFPIKISS1RVIPR1GLP1RVIPR2 | |
| SCHEMBL29702470 | 0.91 | TFPI (0.54) | TFPIVIPR1GLP1RVIPR2F2 | |
| SCHEMBL30198769 | 0.90 | TFPI (0.65) | TFPIVIPR1VIPR2 | |
| SCHEMBL30387150 | 0.90 | VIPR2 (0.62) | TFPIVIPR1GLP1RVIPR2 | |
| SCHEMBL29702389 | 0.90 | TFPI (0.54) | TFPIF2 | |
| SCHEMBL29373287 | 0.89 | TFPI (0.66) | TFPIVIPR1GLP1R | |
| SCHEMBL30242913 | 0.89 | KISS1R (0.61) | TFPIKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116789764-B | Preparation method of anti-coronavirus polypeptide | 北京悦康科创医药科技股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-116789764-A | Preparation method of high-efficiency broad-spectrum anti-coronavirus polypeptide | 北京悦康科创医药科技股份有限公司 | 2023-09-22 | — | — | CN | disclosed |